Cellosaurus 451Lu-MR (CVCL_DG54)

Cell line name 451Lu-MR
Accession CVCL_DG54
Resource Identification Initiative To cite this cell line use: 451Lu-MR (RRID:CVCL_DG54)
Comments Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; GSK1120212).
Sequence variation: Heterozygous for BRAF p.Val600Glu (from parent cell line).
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6357 (451Lu)
Sex of cell Male
Category Cancer cell line
Publications

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023
Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X., Schuchter L.M., Herlyn M., Nathanson K.L.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

Cross-references
Gene expression databases GEO; GSM1199179